Figure. 3From: Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trialLogMAR BCVA changes at weeks 4, 8 and 12. Mean (± SE) logMAR BCVA improved by 0.173 ± 0.033 (p < 0.0001), 0.254 ± 0.033 (p < 0.0001) and 0.272 ± 0.033 (p < 0.0001) compared to baseline at 4, 8, and 12 weeks, respectivelyBack to article page